Baricitinib Improvement Across Regions in Atopic Dermatitis Patients with Baseline Body Surface Area up to 40% and Severe Itch
Carrascosa, José Manuel (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Narcisi, Alessandre (IRCCS Humanitas Research Hospital (Rozzano, Itàlia))
Nomura, Toshifumi (University of Tsukuba)
Ständer, Sonja (University Hospital of Münster (Alemanya))
Vestergaard, Christian (Aarhus University Hospital (Aarhus, Dinamarca))
Sabatino, Silvia (Eli Lilly and Company (Estats Units d'Amèrica))
Grond, Susanne (Eli Lilly and Company (Estats Units d'Amèrica))
Koppelhus, Uffe (Eli Lilly and Company (Estats Units d'Amèrica))
Elrayes, Mohamed (Eli Lilly and Company (Estats Units d'Amèrica))
Chen, Yun-Fei (Eli Lilly and Company (Estats Units d'Amèrica))
Liu, Chunyuan Liu (TigerMed-BDM (New Jersey, Estats Units d'Amèrica))
Wollenberg, Andreas (University Hospital Schleswig-Holstein UKSH)

Data:	2024
Resum:	Introduction: Patients with moderate-to-severe atopic dermatitis (AD) who are most likely to respond to the Janus kinase (JAK) 1/2 inhibitor baricitinib (BARI) are known to have an impacted body surface area (BSA) ≤ 40% and severe itch (numerical rating scale [NRS] ≥ 7], collectively termed 'BARI itch-dominant' patients. Our objective is to build on our previous work by providing a body region-specific, clinical characterization of the BARI itch-dominant patient at baseline and their response to BARI 4 mg. Methods: BREEZE-AD7 was a phase 3 trial in adults with moderate-to-severe AD receiving placebo or 2 mg or 4 mg BARI in combination with topical corticosteroids. Assessing only data from BARI itch-dominant patients, we summarized the baseline characteristics and conducted body region-specific analyses on Eczema Area and Severity Index (EASI) data in order to report the response to placebo versus BARI 4 mg within this patient subtype. Results: BARI 4 mg was highly effective across all body regions; at week 16, 75% improvement was seen in EASI scores (EASI75), and response rates with BARI 4 mg (head/neck, 58. 3%; trunk, 69. 2%; upper extremities, 61. 5%; lower extremities, 87. 5%) all exceeded those with placebo (head/neck: 37. 5%; trunk, 40. 6%; upper extremities, 18. 8%; lower extremities, 40. 6%) as well as the overall EASI75 rates of the intent-to-treat (ITT) population (BARI, 48. 0%; placebo, 23. 0%). At baseline, most BARI itch-dominant patients presented with involvement of all regions (mean regional BSA 22. 7%-40. 3%), highest in the head and neck, mean EASI region scores of 15. 7-24. 0, and considerably severe sign ratings (mean EASI sub-scores: 1. 4-2. 3, out of 3), especially for erythema. Conclusion: BARI itch-dominant patients exhibit AD involvement across all body regions and considerable sign severity, especially erythema. In response to BARI 4 mg, EASI quickly improved across regions, substantially more so in this subtype than in the ITT population.
Nota:	Medical writing assistance in the preparation of this article was provided by Dominika Kennedy, PhD, of Eli Lilly and Company. Statistical analysis was performed by author Chunyuan Liu of Eli Lilly and Company. Quality review and support was provided by Certara Synchrogenix. The support for this assistance was funded by Eli Lilly and Company.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Atopic dermatitis ; Baricitinib ; Body ; Surface area ; Eczema Area and Severity Index ; Itch-dominant ; Janus kinase ; Regional analysis
Publicat a:	Dermatology and Therapy, Vol. 14 Núm. 6 (june 2024) , p. 1561-1573, ISSN 2190-9172

DOI: 10.1007/s13555-024-01171-7
PMID: 38777937

13 p, 1.6 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Articles > Articles de recerca
Articles > Articles publicats